Total Payments
$1,910
2022 Payments
$82.38
Companies
20
Transactions
118
Medicare Patients
3,232
Medicare Billing
$488,050
Payment Breakdown by Category
Food & Beverage$1,897 (99.3%)
Education$12.70 (0.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,897 | 117 | 99.3% |
| Education | $12.70 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $441.71 | 33 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $331.42 | 21 | $0 (2020) |
| Gilead Sciences, Inc. | $318.43 | 18 | $0 (2020) |
| ViiV Healthcare Company | $230.25 | 12 | $0 (2022) |
| Allergan, Inc. | $190.45 | 11 | $0 (2020) |
| Melinta Therapeutics, Inc. | $92.72 | 4 | $0 (2019) |
| AbbVie, Inc. | $48.74 | 3 | $0 (2019) |
| Theravance Biopharma, Inc. | $43.42 | 3 | $0 (2018) |
| Theratechnologies Inc. | $24.15 | 2 | $0 (2018) |
| Paratek Pharmaceuticals, Inc. | $21.89 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $82.38 | 4 | ViiV Healthcare Company ($66.81) |
| 2020 | $197.54 | 11 | Gilead Sciences, Inc. ($41.05) |
| 2019 | $459.42 | 27 | Janssen Biotech, Inc. ($137.15) |
| 2018 | $635.62 | 39 | Janssen Biotech, Inc. ($153.28) |
| 2017 | $534.54 | 37 | Janssen Biotech, Inc. ($130.93) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/20/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: DIABETES | ||||||
| 07/19/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: HIV | ||||||
| 04/07/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: HIV | ||||||
| 02/17/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: HIV | ||||||
| 04/28/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: HIV | ||||||
| 03/02/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.02 | General |
| 02/13/2020 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Respiratory | ||||||
| 02/06/2020 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: ANTIBIOTIC | ||||||
| 02/03/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: HIV | ||||||
| 01/24/2020 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 01/13/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.03 | General |
| 01/09/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/09/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/09/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/06/2020 | Nabriva Therapeutics, plc | Xenleta (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Antibiotic | ||||||
| 12/16/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.06 | General |
| 12/05/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/27/2019 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug), DIFICID, ZINPLAVA | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/21/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2019 | Janssen Biotech, Inc. | Symtuza (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/23/2019 | Janssen Biotech, Inc. | Symtuza (Drug), Juluca | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/07/2019 | Janssen Biotech, Inc. | Symtuza (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/03/2019 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2019 | Janssen Biotech, Inc. | Symtuza (Drug), Juluca | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 09/06/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Virology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 967 | 4,738 | $213,823 | $145,140 |
| 2022 | 14 | 832 | 1,158 | $168,436 | $111,717 |
| 2021 | 10 | 698 | 1,030 | $168,464 | $110,560 |
| 2020 | 11 | 735 | 1,122 | $186,108 | $120,633 |
Total Patients
3,232
Total Services
8,048
Medicare Billing
$488,050
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 101 | 159 | $24,168 | $17,352 | 71.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 111 | 114 | $32,034 | $17,046 | 53.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 172 | 234 | $23,400 | $15,992 | 68.3% |
| J0248 | Injection, remdesivir, 1 mg | Office | 2023 | 13 | 3,400 | $20,400 | $15,418 | 75.6% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 127 | 127 | $19,685 | $14,583 | 74.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 93 | 140 | $20,160 | $14,138 | 70.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 29 | 65 | $18,200 | $12,013 | 66.0% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 118 | 188 | $15,760 | $11,612 | 73.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 63 | $13,356 | $9,611 | 72.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 79 | $8,295 | $4,798 | 57.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $4,680 | $3,416 | 73.0% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 35 | 37 | $4,290 | $3,024 | 70.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 25 | $4,775 | $2,834 | 59.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 30 | 32 | $1,915 | $1,348 | 70.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 16 | $1,760 | $1,292 | 73.4% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 35 | $945.00 | $662.29 | 70.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 218 | 330 | $33,000 | $20,598 | 62.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 115 | 118 | $33,142 | $20,406 | 61.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 31 | 78 | $21,840 | $14,968 | 68.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 138 | $20,976 | $14,134 | 67.4% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 113 | 169 | $13,425 | $10,278 | 76.6% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 83 | 84 | $13,020 | $9,457 | 72.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 74 | 98 | $14,112 | $8,766 | 62.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 31 | 32 | $6,112 | $3,825 | 62.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 15 | $3,180 | $2,480 | 78.0% |
About Dr. Mark Delman, M.D
Dr. Mark Delman, M.D is a Infectious Disease healthcare provider based in Annandale, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1932345931.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Delman, M.D has received a total of $1,910 in payments from pharmaceutical and medical device companies, with $82.38 received in 2022. These payments were reported across 118 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,897).
As a Medicare-enrolled provider, Delman has provided services to 3,232 Medicare beneficiaries, totaling 8,048 services with total Medicare billing of $488,050. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Annandale, VA
- Active Since 12/21/2008
- Last Updated 05/09/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1932345931
Products in Payments
- Symtuza (Drug) $188.31
- AVYCAZ (Drug) $170.09
- PREZCOBIX (Drug) $141.41
- TRIUMEQ (Drug) $114.14
- ISENTRESS (Drug) $101.89
- ZERBAXA (Drug) $98.69
- NOXAFIL (Drug) $85.18
- Baxdela (Drug) $76.06
- DOVATO (Drug) $76.06
- PREZISTA (Drug) $75.30
- VIBATIV (Drug) $43.42
- Mavyret (Drug) $35.27
- PREVYMIS (Drug) $32.56
- NUZYRA (Drug) $21.89
- Xenleta (Drug) $21.68
- CABENUVA (Biological) $21.67
- DALVANCE (Drug) $20.36
- SYMTUZA (Drug) $20.35
- DARAPRIM (Drug) $19.43
- TIVICAY (Drug) $18.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Annandale
Dr. David Wheeler, M.d, M.D
Infectious Disease — Payments: $218,791
Infectious Disease $218,791
Dr. Allan Morrison, M.d, M.D
Infectious Disease — Payments: $33,555
Infectious Disease $33,555
Dr. Donald Poretz, M.d, M.D
Infectious Disease — Payments: $7,242
Infectious Disease $7,242
Dr. Sujata Ambardar, M.d, M.D
Infectious Disease — Payments: $2,487
Infectious Disease $2,487
Jennifer Makhoul, Md, MD
Infectious Disease — Payments: $1,046
Infectious Disease $1,046
Dr. Matthew Swierzbinski, M.d, M.D
Infectious Disease — Payments: $967.03
Infectious Disease $967.03